Evelo Biosciences, Inc. (EVLO) financial statements (2021 and earlier)

Company profile

Business Address 620 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:6978148
Cash and cash equivalents697893
Short-term investments  55
Other undisclosed cash, cash equivalents, and short-term investments (0)(0)
Restricted cash and investments0  
Other undisclosed current assets234
Total current assets:7181152
Noncurrent Assets
Operating lease, right-of-use asset11 
Property, plant and equipment787
Other noncurrent assets121
Total noncurrent assets:20108
TOTAL ASSETS:9191160
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1896
Accounts payable112
Accrued liabilities1695
Debt2  
Other liabilities003
Total current liabilities:20109
Noncurrent Liabilities
Long-term debt and lease obligation402012
Long-term debt, excluding current maturities302012
Operating lease, liability10 
Liabilities, other than long-term debt011
Deferred rent credit 11
Other liabilities000
Total noncurrent liabilities:402114
Total liabilities:603123
Stockholders' equity
Stockholders' equity attributable to parent3060137
Common stock000
Additional paid in capital323259250
Accumulated other comprehensive loss  (0)
Accumulated deficit(293)(199)(113)
Total stockholders' equity:3060137
TOTAL LIABILITIES AND EQUITY:9191160

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:0  
Operating expenses(92)(86)(58)
Other undisclosed operating loss(0)  
Operating loss:(92)(86)(58)
Nonoperating income (expense)(1)11
Investment income, nonoperating(2)12
Other nonoperating income (expense)10(0)
Interest and debt expense  (1)
Loss from continuing operations before income taxes:(93)(85)(58)
Income tax expense(0)(0) 
Net loss:(94)(85)(58)
Other undisclosed net income attributable to parent  1
Net loss attributable to parent:(94)(85)(57)
Preferred stock dividends and other adjustments  (4)
Net loss available to common stockholders, diluted:(94)(85)(61)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(94)(85)(58)
Comprehensive loss:(94)(85)(58)
Other undisclosed comprehensive income, net of tax, attributable to parent 01
Comprehensive loss, net of tax, attributable to parent:(94)(85)(57)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: